1. Confronting the Care Delivery Challenges Arising from Precision Medicine
   Elise C. Kohn et al, 2016, Front. Oncol. CrossRef
2. p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers.
   Eric J Devor et al, 2017, Int J Oncol CrossRef
3. Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer
   Moito Iijima et al, 2017 CrossRef
4. Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
   Ugo Testa et al, 2018, Medicines CrossRef
5. Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)
   Marica Garziera et al, 2018, IJMS CrossRef
6. Clinical Outcomes of TP53 Mutations in Cancers
   Ana I. Robles et al, 2016, Cold Spring Harb Perspect Med CrossRef
7. TP53 Mutations in Breast and Ovarian Cancer.
   Laxmi Silwal-Pandit et al, 2017, Cold Spring Harb Perspect Med CrossRef
8. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors
   S. Y. Cindy Yang et al, 2018, Genome Med CrossRef
9. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations
   Xiangbing Meng et al, 2018, Disease Markers CrossRef
10. TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses
    Victoria Mandilaras et al, 2019, Int J Gynecol Cancer CrossRef
11. Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer
    Megan McDonald et al, 2019, IJMS CrossRef
12. Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers
    Katharina Bischof et al, 2019, Sci Rep CrossRef
13. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach
    Marica Garziera et al, 2019, Cells CrossRef
14. TP53 DNA Binding Domain Mutations Predict Progression-Free Survival of Bevacizumab Therapy in Metastatic Colorectal Cancer.
    Hung-Chih Hsu et al, 2019, Cancers (Basel) CrossRef
15. TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas
    Brandon-Luke L. Seagle et al, 2015, Gynecologic Oncology CrossRef
16. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments
    Yaoqing Shen et al, 2019, Proc Natl Acad Sci USA CrossRef
17. Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing
    Jing Xie et al, 2016, Mol Genet Genomic Med CrossRef
18. The association between codon72 polymorphism of p53 gene and the risk of endometrial cancer: an updating meta-analysis
    Xinzi Lin et al, 2016, Arch Gynecol Obstet CrossRef
19. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer
    Åsa Fransson et al, 2016, J Ovarian Res CrossRef
20. Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer
    Diana P. English et al, 2016, Expert Review of Molecular Diagnostics CrossRef
21. Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.
    Alka Singh et al, 2019, Front Cell Dev Biol CrossRef
22. Whole-exome sequencing reveals critical genes underlying metastasis in oesophageal squamous cell carcinoma
    Wei Dai et al, 2017, J. Pathol CrossRef
23. Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53
    Yajie Chen et al, 2019, Cell Death Dis CrossRef
24. Immunohistochemical expression of p53 in Type I and II epithelial ovarian cancer among Sudanese women: a cross-sectional study
    Aisha Osman Mohamed et al, 2019, F1000Res CrossRef
25. Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)
    Marica Garziera et al, 2019, Cells CrossRef
26. Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties
    Ankush Garg et al, 2019, Biophysical Journal CrossRef
27. Characterization of a TP53 Somatic Variant of Unknown Function From an Ovarian Cancer Patient Using Organoid Culture and Computational Modeling.
    Jianling Bi et al, 2020, Clin Obstet Gynecol CrossRef
28. Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab
    Chi-Wei Tao et al, 2020, Case Reports in Oncological Medicine CrossRef
29. Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers
    Brandon-Luke L. Seagle et al, 2015, Oncotarget CrossRef
30. Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer.
    Ulyana A Boyarskikh et al, 2020, Front Oncol CrossRef
31. Insight updating of the molecular hallmarks in ovarian carcinoma
    Alba Mota et al, 2020, European Journal of Cancer Supplements CrossRef
32. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations
    Talayeh S. Ghezelayagh et al, 2020, Gynecologic Oncology CrossRef
33. A comprehensive analysis of somatic alterations in Chinese ovarian cancer patients
    Yingli Zhang et al, 2021, Sci Rep CrossRef
34. Small Non-Coding-RNA in Gynecological Malignancies
    Shailendra Kumar Dhar Dwivedi et al, 2021, Cancers CrossRef
35. Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations
    Isao Otsuka, 2021, IJMS CrossRef
36. Mutated p53 in HGSC—From a Common Mutation to a Target for Therapy
    Aya Saleh et al, 2021, Cancers CrossRef
37. Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor
    Zih-Yin Lai et al, 2021, IJMS CrossRef
38. null
    Khalid El Bairi et al, 2021 CrossRef
39. Estrogen Receptor-beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)
    Chetan C. Oturkar et al, 2022, Cancers CrossRef
40. null
    Anam Beg et al, 2022 CrossRef
41. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
    Kristina W. Thiel et al, 2022, JCO CrossRef